Relapsed/refractory al amyloidosis

Clinical trials for Relapsed/refractory al amyloidosis explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory al amyloidosis trials appear

Sign up with your email to follow new studies for Relapsed/refractory al amyloidosis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Experimental CAR t therapy takes aim at stubborn AL amyloidosis

Disease control Recruiting now

This early-phase trial is testing a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to other therapies. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to attack two specific targets on the abnormal…

Matched conditions: RELAPSED/REFRACTORY AL AMYLOIDOSIS

Phase 1 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control

Last updated Jul 25, 2026 00:00 UTC

Relapsed/refractory al amyloidosis

Get alerted when new Relapsed/refractory al amyloidosis trials appear

Experimental CAR t therapy takes aim at stubborn AL amyloidosis